Evvy's $40M Funding Round Signals a New Era in Women's Health Data

Unlocking Women's Health Through Data

As the healthcare industry grapples with the challenges of precision medicine, companies like Evvy are leading a crucial conversation about the data gap that has long defined women's health. Today, I'm writing about how Evvy's $40 million Series B funding round isn't just another tech investment—it's a pivotal moment in reshaping how we understand female biology and health outcomes.

"You can't build precision medicine for women on datasets that never adequately measured female biology in the first place," said Priyanka Jain, CEO and co-founder of Evvy.

The investment, led by Catalio Capital Management, signals investor confidence in Evvy's vision to build a robust dataset that bridges biological insights with clinical outcomes. This is more than just another funding milestone; it's about redefining how healthcare addresses the needs of half the population that has historically been underrepresented in research.

From Test Kits to Clinical Insights

Evvy, launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, operates what it calls the world's only at-home CLIA- and CLEP-certified mNGS test for analyzing vaginal microbes. The company's approach is unique in its direct-to-consumer model, enabling users to collect their own samples and receive results that are then interpreted by clinicians registered on Evvy's platform.

This process ensures that the data isn't just collected—it's contextualized and actionable. "When a patient receives their results, they are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps, including personalized prescription care when relevant," Jain explained to TechCrunch.

Since its inception, Evvy has served more than 100,000 patients across the United States and collaborates with over 3,000 practitioners. Importantly, the company has already generated 15 peer-reviewed publications and abstracts, identifying novel bacterial subtypes and hundreds of previously uncatalogued vaginal microbiome genomes.

The Need for Comprehensive Data

One of the most compelling aspects of Evvy's strategy is its recognition that precision medicine, as currently practiced, lacks high-quality, representative data on female biology. This is a critical shortcoming because traditional research often overlooks key biological differences between sexes.

Jain highlighted how current AI models struggle with questions about women's health due to insufficient datasets. "That's why I believe AI for women's health needs to be paired with new biological data at scale," she noted. "AI can help us identify patterns across molecular signals, hormones, symptoms, treatments, fertility outcomes, and other biomarkers that traditional medicine has struggled to connect."

This point is not just academic—it's a practical necessity. Without adequate datasets, we remain stuck in a system where women's health issues are often dismissed as 'unexplained' or brushed aside with vague diagnoses. Evvy's approach offers a potential pathway toward change.

AI-Driven Personalization

Evvy has taken its data-driven mission a step further by launching EvvyAI, an AI assistant designed to interpret vaginal microbiome data in real time. The tool translates complex datasets into actionable insights for users while directing them to clinicians for more nuanced questions.

This integration of AI and biological data is significant. It allows for a personalized experience that is tailored not just to symptoms but to the unique microbial profile of each individual. As Evvy expands its research capabilities, it's creating an infrastructure for understanding how microbiomes influence fertility outcomes, gynecological cancers, preterm births, and recurrent pregnancy loss.

Looking Forward: Beyond Vaginal Health

Evvy's ambition extends far beyond vaginal health. The company is now venturing into the fertility space, marking its first major expansion beyond its core offering. This move underscores a broader strategy to connect data from one aspect of women's biology to another, creating a holistic view of female health.

Jain emphasized how collecting data in women's health can help move the industry away from accepting unexplained symptoms or conditions. "Women shouldn't have to accept unexplained infertility, unexplained recurrence, or unexplained symptoms as answers when what they often mean is that medicine hasn't caught up to the data yet," she said.

This shift is not only about better clinical outcomes—it's about empowering women with information and choices. Evvy envisions a future where tools like its at-home test can become as routine as Pap smears, offering continuous, data-rich insights into a range of health conditions across the female lifespan.

Industry Implications

The success of companies like Evvy is part of a larger trend in personalized medicine—particularly in women's health. As we continue to see innovation in this space, it becomes increasingly clear that progress depends on data that represents the full spectrum of human biology.

Other players in the vaginal health space, such as Juno Bio, Tiny Health, and Daye, are also contributing to a growing ecosystem that challenges outdated assumptions about women's bodies. Together, they're pushing the industry toward more inclusive and effective healthcare solutions.

A Vision for the Future

Jain's vision is ambitious: to develop an at-home, non-invasive test that can provide regular, data-rich insights into a wide array of health conditions—from infections and inflammation to fertility, PCOS, endometriosis, and even HPV progression. It's a future where women can take charge of their health with tools powered by real-time data and clinical support.

"I don't think we can wait for traditional research methods to catch up," she said. "I believe women, as patients, can be part of pushing the industry forward."

Evvy's journey is not just about technology or investment—it's about reimagining what it means to care for women's health in a data-driven age. With its $40 million funding round and growing influence, Evvy is setting a new standard for how we approach female biology in medicine.

This is not just a story of funding or product development; it's a story of innovation that centers on inclusivity, personalization, and patient empowerment. As Evvy continues to build its dataset and refine its AI tools, the promise of precision medicine for women becomes ever more tangible.